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Objectives The aim of this study was to examine the prognostic value of lipoprotein-associated phospholipase A2 (Lp-PLA2)
associated with high-density lipoprotein (HDL) (HDL-Lp-PLA2) in patients with stable coronary artery disease
(CAD).
Background Lp-PLA2 is a novel risk factor for cardiovascular disease. It has been postulated that the role of Lp-PLA2 in ath-
erosclerosis may depend on the type of lipoprotein with which it is associated.
Methods Total plasma Lp-PLA2 and HDL-Lp-PLA2 mass and activity, lipids, and C-reactive protein were measured in 524
consecutive patients with stable CAD who were followed for a median of 34 months. The primary endpoint was
cardiac death, and the secondary endpoint was hospitalization for acute coronary syndromes, myocardial revas-
cularization, arrhythmic event, or stroke.
Results Follow-up data were obtained from 477 patients. One hundred twenty-three patients (25.8%) presented
with cardiovascular events (24 cardiac deaths, 47 acute coronary syndromes, 28 revascularizations, 22 ar-
rhythmic events, and 2 strokes). Total plasma Lp-PLA2 mass and activity were predictors of cardiac death
(hazard ratio [HR]: 1.013; 95% confidence interval [CI]: 1.005 to 1.021; p  0.002; and HR: 1.040; 95% CI:
1.005 to 1.076; p  0.025, respectively) after adjustment for traditional risk factors for CAD. In contrast, HDL-
Lp-PLA2 mass and activity were associated with lower risk for cardiac death (HR: 0.972; 95% CI: 0.952 to 0.993;
p  0.010; and HR: 0.689; 95% CI: 0.496 to 0.957; p  0.026, respectively) after adjustment for traditional risk
factors for CAD.
Conclusions Total plasma Lp-PLA2 is a predictor of cardiac death, while HDL-Lp-PLA2 is associated with lower risk for cardiac
death in patients with stable CAD, independently of other traditional cardiovascular risk factors. (J Am Coll
Cardiol 2012;60:2053–60) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.06.057p
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nLipoprotein-associated phospholipase A2 (Lp-PLA2), also
known as platelet-activating factor (PAF) acetylhydrolase,
expresses a Ca2-independent phospholipase A2 activity
nd catalyzes the hydrolysis of the ester bond at the sn-2
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accepted June 19, 2012.osition of PAF and oxidized phospholipids (1,2). These
hospholipids are formed during oxidative modification of
ow-density lipoprotein (LDL) in the arterial intima and
ay play important roles in atherogenesis (1,2). Lp-PLA2 is
produced by inflammatory cells such as macrophages, foam
cells, T cells, hepatic Kupffer cells, and mast cells (3,4).
Lp-PLA2 circulates in plasma in active form bound to
arious lipoproteins, primarily to LDL, whereas a minor
roportion of circulating enzyme is also associated with
igh-density lipoprotein (HDL), lipoprotein(a), and rem-
ant lipoproteins (1,5). Lp-PLA2 is located in advanced
rupture-prone plaques, from which it can be released into
the circulation (2,6).
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HDL-Lp-PLA2 and Prognosis in Stable CAD November 13, 2012:2053–60Several epidemiologic studies
suggest that plasma Lp-PLA2 is
an independent predictor of car-
diovascular events in primary and
secondary prevention (7–15). A
recent meta-analysis (9), which in-
cluded 79,036 participants with or
without coronary artery disease
(CAD) from 32 prospective stud-
ies, showed that Lp-PLA2 activity
and mass each had a continuous
association with the risk for CAD.
Particularly, in the setting of stable
CAD, it has been shown that Lp-
PLA2 is a significant predictor of
nonfatal adverse cardiovascular
outcomes independent of tradi-
tional clinical risk factors (10).
It has been postulated that the
role of Lp-PLA2 in atherosclerosis
may depend on the type of lipo-
protein with which it is associated
(16,17). In contrast to total Lp-
PLA2 plasma enzyme, which
mainly represents the LDL-
associated Lp-PLA2, several lines
of evidence suggest that HDL-
associated Lp-PLA2 (HDL-Lp-
PLA2) may substantially contrib-
ute to the antiatherogenic activities of HDL (16). However,
the clinical value of HDL-Lp-PLA2 as a potent inhibitor of
he atherosclerotic process remains to be established. Thus, the
im of the present study was to explore whether HDL-Lp-
LA2 can predict future cardiovascular events in patients with
stable CAD.
Methods
Study population. All patients with stable CAD who
attended the outpatient cardiologic department of 3 large
hospitals in Athens between 2006 and 2009 were asked to
participate in the study. All patients were participants of the
LAERTES (Lipoprotein-Associated phospholipasE A2 in
stable coronary aRTEry diSease Study), which is an ongo-
ing prospective, hospital-based study investigating the prog-
nostic impact of Lp-PLA2 in stable CAD. We initially
creened 620 patients, of whom 524 satisfied the selection
riteria and made up the final sample. Subjects were
ncluded in the study if they had been previously hospital-
zed for acute coronary syndromes (ACS), had undergone
yocardial revascularization intervention, or had undergone
oronary angiography for chest pain and there was docu-
entation of CAD. Coronary artery stenosis was defined as
50% reduction in luminal diameter of any of the 3
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
apo  apolipoprotein
CAD  coronary artery
disease
CI  confidence interval
HDL  high-density
lipoprotein
HDL-Lp-PLA2  high-density
lipoprotein–associated
lipoprotein-associated
phospholipase A2
HR  hazard ratio
hsCRP  high-sensitivity
C-reactive protein
IPAQ  International
Physical Activity
Questionnaire
LDL  low-density
lipoprotein
Lp-PLA2  lipoprotein-
associated phospholipase A2
MET  metabolic
equivalent
PAF  platelet-activating
factororonary arteries or their primary branches.Exclusion criteria were ACS or coronary artery bypass
rafting within the previous 6 months, clinical evidence of
eart failure, chronic renal failure (creatinine level 2
g/dl), age 75 years, and coexistent neoplasm or inflam-
atory disease.
All patients underwent clinical examination and blood
esting. The following definitions were used: hypertension,
lood pressure 140/90 mm Hg and/or antihypertensive
reatment; hypercholesterolemia, total cholesterol 200
g/dl (5.2 mmol/l); diabetes mellitus, fasting plasma
lucose 125 mg/dl (6.94 mmol/l) and/or glucose-
owering treatment. Smoking habits were recorded, and
ody mass index (weight in kilograms divided by the
quare of height in meters) and waist circumference were
lso evaluated.
Dietary habits were evaluated using a validated diet score
hat assesses adherence to Mediterranean dietary patterns
18). The score is derived from a questionnaire that includes
major food groups (nonrefined cereals, fruit, vegetables,
egumes, potatoes, fish, meat and meat products, poultry,
nd full-fat dairy products), as well as olive oil and alcohol
ntake. Each question is scored on a scale of 0 through 5
ccording to the frequency of food consumption per week,
nd the diet score ranges between 0 and 55. Higher values
f this diet score indicate greater adherence to the Medi-
erranean diet.
Physical activity was also assessed using a translated
hort version of the International Physical Activity Ques-
ionnaire (IPAQ), an index of weekly energy expenditure
sing the frequency (times per week), duration (minutes per
ime), and intensity of physical activity. The IPAQ mea-
ures are expressed as metabolic equivalent (MET)–minutes
er week. One MET is defined as 3.5 ml oxygen · kg1 ·
min1. We used the following MET estimates of the
PAQ: vigorous physical activity  8 METs, moderate
activity  4 METs, walking on average  3.3 METs, and
sitting  0 METs. For calculating the overall METs of
physical activity, each category was multiplied by its special
MET estimate value. The IPAQ has reasonable measure-
ment properties for monitoring population levels of physical
activity (19).
Finally, all patients underwent echocardiography, and the
ejection fraction of the left ventricle was measured using the
biplane method of discs (modified Simpson’s rule) (20).
Measurement of Lp-PLA2 activity and mass in total
lasma and on HDL. Peripheral blood samples were
ollected from patients after an overnight fast between 8
AM and 10 AM. Lp-PLA2 activity in total plasma and in
apolipoprotein (apo) B–depleted plasma, after the sedimen-
tation of all apo B–containing lipoproteins with dextran
sulfate-magnesium chloride (HDL-Lp-PLA2 activity),
was determined using the trichloroacetic acid precipita-
tion procedure using [3H]-PAF (100 mol/l final con-
centration) as a substrate (21,22). Fifty microliters of total
plasma diluted 1:50 v/v with 4-(2-hydroxyethyl)-1-pipera-
zineethanesulfonic acid buffer (pH 7.4) or the apo B–depleted
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November 13, 2012:2053–60 HDL-Lp-PLA2 and Prognosis in Stable CADplasma (diluted 1:3 v/v with 4-[2-hydroxyethyl]-1-pipera-
zineethanesulfonic acid) was used as a source of the enzyme.
The reaction was performed for 10 min at 37°C, and Lp-PLA2
activity was expressed as nanomoles of PAF degraded per
minute per milliliter of plasma.
Lp-PLA2 mass was determined by a dual monoclonal
antibody immunoassay standardized to recombinant Lp-
PLA2 (PLAC Test, diaDexus, Inc., South San Francisco,
A), following the manufacturer’s instructions (23). Lp-
LA2 mass was measured in plasma and in apo B–depleted
plasma, prepared as described earlier (HDL-Lp-PLA2
mass), as we have previously described (24). We used 10 l
f undiluted plasma or apo B–depleted plasma as the source
f the enzyme. It should be noted that in all apo B–depleted
lasma samples, there were no detectable amounts of apo B,
hereas the apo A-1 concentration was similar to that
etermined in whole plasma of each individual patient (data
ot shown). Furthermore, according to our previously pub-
ished results, the Lp-PLA2 measured in apo B–depleted
plasma is exclusively associated with HDL (24,25). The
intra-assay and interassay coefficients of variation of Lp-
PLA2 measurements in the apo B–depleted plasma were
.4% and 8.9%, respectively, for activity and 5.5% and 7.5%,
espectively, for mass.
iochemical measurements. Serum levels of total choles-
erol, HDL cholesterol, and triglycerides were measured
nzymatically using an automatic analyzer (Dimension
XL; Dade Behring, Marburg, Germany). LDL choles-
erol was calculated according to the Friedewald formula:
DL cholesterol  total cholesterol  (triglycerides/5 
HDL cholesterol). Serum levels of apo A-1 and apo B
were measured by immunonephelometry using a BN
Prospect analyzer (Dade Behring). C-reactive protein
was assayed using high-sensitivity particle-enhanced im-
munonephelometry (N Latex, Dade Behring), with a
range of 0.175 to 1,100 mg/l. The intra-assay and
interassay coefficients of variation of all measured bio-
chemical parameters were 5%.
Follow-up. After the initial appointment, patients were
followed up at 6-month intervals by telephone interview by
trained cardiologists. In addition, between September and
December 2010, all patients were contacted to assess their
status. When a patient was not found, data were obtained by
telephone interview with family members or the treating
physician. The primary endpoint was cardiovascular death,
and the secondary endpoint was readmission for ACS,
arrhythmic events, stroke, or myocardial revascularization
(percutaneous coronary intervention or coronary artery
bypass grafting) due to clinical deterioration. Noncardiac
deaths were not included in the analysis. In case of death,
death certificates were obtained and the cause of death
was verified by verbal or written contact with the treating
physician.
The study was approved by the ethics committee of our
institution, and all subjects gave their informed consent. LStatistical analysis. Continuous variables are presented as
mean  SD, while non-normally distributed variables are
presented as medians and interquartile ranges. We used
Student t tests for independent samples to compare means
for normally distributed variables and Mann-Whitney tests
for skewed variables and chi-square tests for qualitative
variables. The Shapiro-Wilk test for normality was used to
evaluate the t-test assumption. Bivariate correlations were
performed using Pearson correlation coefficients and linear
regression analysis using beta regression coefficients and
corresponding SE. Hazard ratios (HRs) and corresponding
95% confidence intervals (CIs) were calculated using Cox
proportional-hazards models. The natural logarithm of
high-sensitivity C-reactive protein (hsCRP) was used
because of its skewed distribution. Proportionality of
hazards was assessed using Schoenfeld residuals and the linear
assumption using Martingale residuals. Crude survival curves
were constructed using the Kaplan-Meier method to describe
the incidence of death over time, and log-rank tests were
applied to evaluate differences between groups.
A p value0.05 was considered significant. SPSS version
13 (SPSS, Inc., Chicago, Illinois) and Stata version 9.1
(StataCorp LP, College Station, Texas) were used.
Results
Baseline characteristics. We initially recruited 524 con-
secutive patients with stable CAD. Follow-up data were not
obtained in 39 patients for several reasons (declined to
participate, wrong addresses, etc.). In addition, 8 patients
whose deaths were considered noncardiovascular were ex-
cluded. Therefore, analysis was confined to 477 patients
with CAD. Baseline characteristics according to occurrence
of death are shown in Table 1.
Cardiac events during follow-up. The median period of
follow-up was 34 months (interquartile range: 24 to 40
months). One hundred twenty-three patients (25.8%) pre-
sented with cardiac events during the follow-up period. Of
these, 24 died (cardiac death) (5%), 47 (9.9%) developed
ACS, 28 (5.9%) underwent myocardial revascularization
procedures (percutaneous coronary intervention or coro-
nary artery bypass grafting) because of clinical deteriora-
tion, 22 (4.6%) had arrhythmic events, and 2 (0.42%) had
strokes. Patients who underwent revascularization proce-
dures during ACS were assigned once in the group with
ACS.
Associations of Lp-PLA2 and HDL-Lp-PLA2. There
was a significant correlation between Lp-PLA2 activity and
p-PLA2 mass (r  0.526, p  0.001). Lp-PLA2 activity
was also positively correlated with LDL cholesterol and apo
B levels (r  0.486, p  0.001, and r  0.529, p  0.001,
respectively). Similarly, Lp-PLA2 mass was positively cor-
elated with LDL cholesterol and apo B (r  0.383, p 
.001, and r  0.260, p  0.001, respectively). Both
p-PLA2 activity and Lp-PLA2 mass were positively cor-
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HDL-Lp-PLA2 and Prognosis in Stable CAD November 13, 2012:2053–60related with hsCRP (r  0.179, p  0.001, and r  0.190,
p  0.001, respectively). In addition, Lp-PLA2 activity was
ositively associated with smoking (beta  0.168, SE 
.113, p  0.028).
There was a significant association between HDL-Lp-
LA2 activity and HDL-Lp-PLA2 mass (r  0.765, p 
.001). HDL-Lp-PLA2 activity was also positively corre-
lated with HDL cholesterol and apo A-1 levels (r  0.586,
p  0.001, and r  0.374, p  0.001, respectively).
Similarly, HDL-Lp-PLA2 mass was positively correlated with
DL cholesterol and apo A-1 (r 0.451, p 0.001, and r
.308, p  0.001, respectively). Finally, HDL-Lp-PLA2
activity was inversely correlated with waist circumference
(r  0.107, p  0.043) and current smoking (beta 
Baseline Characteristics of the Study PopulatioAccording to the Occurrence of Events (CardiacTable 1 B seline Charact ris ics of the StuAccording to the Occurrence of Eve
Parameter Even
Age (yrs)
Men 21 (
Current smokers 6 (
Hypertension 17 (
Diabetes mellitus 12 (
Family history of CAD 8 (
LV ejection fraction 39
Previous ACS 20 (
Body mass index (kg/m2) 29
Waist circumference (cm) 1
Dietary score 33
Physical exercise (METs-min/week) 986 (
Total cholesterol (mg/dl) 169
Triglycerides (mg/dl) 99.0 (
LDL cholesterol (mg/dl) 110
HDL cholesterol (mg/dl) 37
Apo A-1 (mg/dl) 119
Apo B (mg/dl) 90
Lp-PLA2 mass (ng/ml) 354
Lp-PLA2 activity (nmol · ml
–1 · min–1) 39
HDL-Lp-PLA2 mass (ng/ml) 65
HDL-Lp-PLA2 activity (nmol · ml
–1 · min–1) 3
Lp-PLA2/HDL-Lp-PLA2 (mass) 6
Lp-PLA2/HDL-Lp-PLA2 (activity) 12.5 (
hsCRP (mg/l) 3.5 (
Drug therapy
Antiplatelet treatment 22 (
Lipid-lowering medication 19 (
Statins 19 (
Ezetimibe* 2 (
Fibrates*
Nicotinic acid*
Beta-blockers 20 (
ACE inhibitors or AT1 blockers 15 (
Thyroid substitution therapy 1 (
Values are mean  SD, n (%), or median (interquartile range). *Alone
ACE  angiotensin-converting enzyme; ACS  acute coronary
coronary artery disease; HDL  high-density lipoprotein; HDL-Lp-P
high-sensitivity C-reactive protein; LDL  low-density lipoprotein; L
MET  metabolic equivalent.0.373, SE 0.168, p 0.028), while an inverse associationwas observed between HDL-Lp-PLA2 mass and diabetes
mellitus (beta  6.443, SE  2.754, p  0.02).
Predictors of cardiovascular events during follow-up.
Univariate Cox regression analysis revealed that total plasma
Lp-PLA2 activity and mass, HDL-Lp-PLA2 activity and
mass, ratios of Lp-PLA2 to HDL-Lp-PLA2 activity and
ass, and the natural log of hsCRP predicted the occur-
ence of cardiac death (Table 2). Multivariate Cox regres-
ion analysis showed that Lp-PLA2 activity and mass,
DL-Lp-PLA2 activity and mass, the ratio of Lp-PLA2 to
DL-Lp-PLA2 mass, and the natural log of hsCRP were
independent predictors of cardiac death after adjustment for
conventional risk factors (age, sex, diabetes mellitus, total
cholesterol, hypertension, smoking, and family history of
th)pulation
Cardiac Death)
24) No Event (n  453) p Value
61 9 0.001
) 384 (84.8%) 0.712
) 129 (28.5%) 0.712
) 285 (62.9%) 0.433
) 150 (33.1%) 0.089
) 158 (34.9%) 0.877
3.2 52.7 9.5 0.001
) 366 (80.8%) 0.756
.4 28.7 4.3 0.546
2.6 102.5 10.9 0.058
.9 31.5 5.2 0.244
,875) 1,600 (612–3,612) 0.275
3.2 173.2 38.4 0.624
60.2) 119.0 (87.0–168.0) 0.151
1.9 104.8 32.7 0.407
.1 44.5 10.2 0.002
7.7 137.3 22.5 0.001
3.9 90.6 22.8 0.957
0.8 311.8 55.9 0.001
3.1 33.8 11.5 0.032
7.9 80.9 24.9 0.006
.5 3.9 1.5 0.024
.9 4.3 1.7 0.001
.5) 8.8 (6.4–12.3) 0.001
.4) 1.9 (1.0–4.4) 0.004
) 421 (92.9%) 0.814
) 373 (82.3%) 0.692
) 355 (78.4%) 0.926
33 (7.3%) 0.848
7 (1.5%) 0.540
5 (1.1%) 0.605
) 359 (79.2%) 0.629
) 270 (59.6%) 0.778
15 (3.3%) 0.819
ombination with statins.
es; apo  apolipoprotein; AT1  angiotensin II type 1; CAD 
high-density lipoprotein–associated phospholipase A2; hsCRP 
 lipoprotein-associated phospholipase A2; LV  left ventricular;nDeady Po
nts (
t (n 
67 9
87.5%
25.0%
70.8%
50.0%
33.3%
.4 1
83.3%
.2 4
07 1
.1 4
331–3
.1 6
79.0–1
.7 5
.9 8
.3 1
.9 3
.3 7
.1 1
.8 2
.1 1
.7 3
9.1–19
1.8–19
91.7%
79.2%
79.2%
8.3%)
0
0
83.3%
62.5%
4.1%)
or in c
syndrom
LA2 CAD) (Table 2).
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November 13, 2012:2053–60 HDL-Lp-PLA2 and Prognosis in Stable CADTo address the problem of overfitting, that is, few events
(cardiac deaths) for the covariates used, a new model was
fitted using age as the unique covariate, because in univar-
iate analysis, it was the only risk factor significantly associ-
ated with the outcome. All tested variables were indepen-
dent predictors of cardiac death. In particular, the HR for
HDL-Lp-PLA2 mass was 0.967 (95% CI: 0.948 to 0.988;
p 0.002) and for HDL-Lp-PLA2 activity was 0.685 (95%
CI: 0.508 to 0.952; p  0.023).
We applied Cox proportional-hazards models to assess
the incidence of cardiac death according to tertiles of
HDL-Lp-PLA2 mass and the ratio of Lp-PLA2 to HDL-
Lp-PLA2 (mass) after adjustments for classic risk factors.
Importantly, patients in the upper tertile of HDL-Lp-
PLA2 mass (90.78 ng/ml) had 75% less possibility of
cardiac death compared with patients in the lower tertile
(68.15 ng/ml) (HR: 0.250; 95% CI: 0.080 to 0.785; p 
0.018), while patients in the upper tertile of the ratio of
Lp-PLA2 to HDL-Lp-PLA2 (mass) (4.62) had 4 times
higher risk for cardiac death compared with patients in the
lower tertile (3.47) (HR: 4.243; 95% CI: 1.193 to 15.092;
p  0.026). Figure 1 presents unadjusted Kaplan-Meier
urvival curves stratified according to tertiles of HDL-Lp-
LA2 mass and ratio of Lp-PLA2 to HDL-Lp-PLA2 mass.
inally, in the subgroup of patients with low HDL choles-
erol levels (men with HDL cholesterol 40 mg/dl and
omen with HDL cholesterol 50 mg/dl), HDL-Lp-
LA2 mass was an independent predictor of cardiac death
after adjustment for conventional risk factors (HR: 0.951;
95% CI: 0.908 to 0.996; p  0.033).
Regarding the secondary endpoints, in univariate analysis,
HDL-Lp-PLA2 activity and mass were associated with
ower risk for ACS (for HDL-Lp-PLA2 activity: HR:
.771; 95% CI: 0.618 to 0.962; p  0.021; for HDL-Lp-
PLA2 mass: HR: 0.987; 95% CI: 0.974 to 1.000; p 
0.044). However, this association was abolished when ad-
justment for conventional risk factors was performed. Im-
portantly, when we examined the prognostic value of
HDL-Lp-PLA2 for the combined endpoint of cardiac
death and ACS (n  71) adjusted for conventional risk
factors, a significant inverse association was observed for
Univariate and Multivariate Associations Between Total Plasma Lp-PLatios of Lp-PLA2 to HDL-Lp-PLA2 Mass and Activity, Natural Log of hTable 2 Univariate nd Multivariate Associations Between Total PRatios of Lp-PLA2 to HDL-Lp-PLA2 Mass and Activity, Nat
Variable
Univariate
HR 95% CI
Lp-PLA2 (mass) 1.015 1.007–1.023
Lp-PLA2 (activity) 1.034 1.003–1.067
HDL-Lp-PLA2 (mass) 0.974 0.955–0.993
HDL-Lp-PLA2 (activity) 0.691 0.504–0.946
Lp-PLA2/HDL-Lp-PLA2 (mass) 1.432 1.268–1.619
Lp-PLA2/HDL-Lp-PLA2 (activity) 1.042 1.008–1.076
ln(hsCRP) 1.851 1.321–2.593
*Adjusted simultaneously for age, sex, smoking status, presence of hypertension, diabetes mellit
CI  confidence interval; HR  hazard ratio; other abbreviations as in Table 1.HDL-Lp-PLA2 mass (HR: 0.986; 95% CI: 0.975 to 0.998;p  0.021) and for HDL-Lp-PLA2 activity (HR: 0.796;
95% CI: 0.654 to 0.968; p  0.023).
Finally, the ratio of Lp-PLA2 to HDL-Lp-PLA2 mass was
also associated with the development of any cardiovascular
event (HR: 1.114; 95% CI: 1.015 to 1.224; p 0.023), which
remained even after adjustments to conventional risk factors
(HR: 1.110; 95% CI: 1.001 to 1.230; p  0.048).
Discussion
In this prospective study of patients with stable CAD, we
demonstrate for the first time that HDL-Lp-PLA2 (mass or
ctivity) is inversely associated with future cardiac mortality
r the combined endpoint of cardiac death and ACS
ndependently of the classic risk factors. In addition, HDL-
p-PLA2 mass was an independent predictor of cardiac
eath after adjustment for conventional risk factors in the
atients with low HDL cholesterol levels. The present study
urther shows that the ratio of the total plasma Lp-PLA2 to
DL-Lp-PLA2 mass is also an independent predictor of
cardiac death.
In accordance with previously published data, the total
plasma Lp-PLA2 (mass or activity) is associated positively
ith future cardiac mortality independently of the classic
isk factors. Indeed, previous studies have consistently
emonstrated that the total plasma Lp-PLA2, which pri-
marily represents the LDL-associated enzyme (16,21), is
associated with cardiovascular events in subjects both with
and without documented CAD, and these data support the
hypothesis that this enzyme may be a causal mediator of
atherosclerosis and plaque instability (7–15).
In our study, we recruited patients with stable CAD. The
majority of previous clinical studies have reported data on
patients with ACS (11,12) or on mixed populations com-
prising patients with ACS and stable CAD (13,14). Thus,
there are limited data concerning only patients with stable
CAD. In this regard, Sabatine et al. (10) studied 3,766
patients with stable CAD who were followed for a median
of 4.8 years. They found that increased levels of Lp-PLA2
mass were significant predictors of nonfatal adverse cardio-
vascular outcomes, independent of traditional clinical risk
ass and Activity, HDL-Lp-PLA2 Mass and Activity,, and Cardiac Death at Follow-UpLp-PLA2 Mass nd Activity, HDL-Lp-PLA2 Mass and Activity,
og of hsCRP, and Cardiac Death at Follow-Up
Multivariate*
p Value HR 95% CI p Value
0.001 1.013 1.005–1.021 0.002
0.033 1.040 1.005–1.076 0.025
0.007 0.972 0.952–0.993 0.010
0.021 0.689 0.496–0.957 0.026
0.001 1.476 1.217–1.791 0.001
0.014 1.036 0.998–1.075 0.064
0.001 1.731 1.234–2.429 0.002
l cholesterol, and family history of coronary artery disease.A2 MsCRPlasm
ural Lfactors and hsCRP. However, they failed to find an associ-
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HDL-Lp-PLA2 and Prognosis in Stable CAD November 13, 2012:2053–60ation with cardiovascular deaths after multivariate adjust-
ments. In the present study, there was an independent
association of total plasma Lp-PLA2 with cardiac deaths.
A small proportion of Lp-PLA2 in plasma is bound on
HDL and previous studies have suggested that HDL-Lp-
PLA2 may exert antiatherogenic and anti-inflammatory
ffects. This assumption is based on findings from in vitro
xperiments as well from in vivo studies in animal models.
n vitro studies have shown that Lp-PLA2 contributes to
Figure 1 Unadjusted Kaplan-Meier Survival Curves
Unadjusted Kaplan-Meier survival curves for cardiac death classified by tertiles of
high-density lipoprotein–associated phospholipase A2 (HDL-Lp-PLA2) mass (A)
and ratio of Lp-PLA2 to HDL-Lp-PLA2 mass (B).the HDL-mediated inhibition of cell stimulation induced Hby oxidized LDL (26). Furthermore, adenoviral transfer of
the human plasma Lp-PLA2 gene in atherosclerosis-prone
apo E-/- mice induced a 3.5-fold reduction of macrophage
dhesion ex vivo and a 2.6-fold reduction in macrophage
oming in vivo. These inhibitory effects were independent
f the function of HDL as a cholesterol acceptor (27). Gene
ransfer of Lp-PLA2 in apo E
-/-/mice also reduced the
deposition of oxidized lipoproteins and the accumulation of
macrophages and smooth muscle cells in the arterial wall, in
parallel with the inhibition of neointima formation induced
by endothelial denudation and reduction of spontaneous
atherosclerosis (28). Consistent with these results, local
adenovirus-mediated Lp-PLA2 gene transfer at the site of
njury resulted in a significant reduction in neointima
ormation in balloon-denuded aorta in cholesterol-fed rab-
its (29). Similarly, local expression of Lp-PLA2 reduces
the accumulation of oxidized lipoproteins and inhibits
inflammation, shear stress-induced thrombosis, and neoin-
tima formation in balloon-injured carotid arteries in nor-
molipidemic rabbits (30). It should be emphasized that all
these studies were conducted in animal models exhibiting a
reverse lipoprotein profile compared with humans (higher
HDL than LDL levels), while the vast majority of plasma
Lp-PLA2 in these animals is associated with HDL (31), so these
esults may not be relevant for the situation in humans.
There are very few published data regarding HDL-Lp-
LA2 in humans. Previous data published by our group
showed that the distribution of Lp-PLA2 among HDL
subclasses is heterogenous, and this enzyme is primarily
associated with a small HDL subfraction denoted as
HDL-3c or very high-density lipoprotein–1 (21,24,25).
This subfraction contains only a small proportion of the
total plasma HDL cholesterol (21). In patients with meta-
bolic syndrome, HDL-Lp-PLA2 activity was lower com-
ared with those without metabolic syndrome and was
nversely associated with the degree of insulin resistance
32,33). Low plasma levels of HDL-Lp-PLA2 are observed
in dyslipidemic type IIB and type IV patients characterized
by elevated triglyceride levels, a defect that is significantly
improved with fenofibrate treatment (25,34). Consistent
with these suggestions are the results of the present study,
the first prospective study to evaluate whether HDL-Lp-
PLA2 can predict future cardiovascular events in patients
ith stable CAD. Our results show for the first time that
DL-Lp-PLA2 mass or activity is associated with lower
isk for cardiac death independently of other traditional risk
actors for CAD.
Our results further reveal that the ratio of total plasma
p-PLA2 to HDL-Lp-PLA2 mass is also independently
ssociated with the risk for development of any cardiovas-
ular event. This finding supports our previously published
ata showing that this ratio may represent a potential
arker of atherogenicity in dyslipidemic type IIA patients
22,35). Furthermore, other investigators have reported that
n elevation in the ratio of LDL-associated Lp-PLA2 to
DL-Lp-PLA2 is associated with an increased incidence of
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inflammation in these patients (36).
These results may be of particular importance in view of
the phase 2 clinical studies showing that the selective
Lp-PLA2 inhibitor darapladib significantly reduces plasma
p-PLA2 activity (37,38) and prevents expansion of the
necrotic core volume in the coronary arteries of patients
with CAD (38), suggesting that darapladib may be a
potentially useful therapeutic agent for the reduction of
residual cardiovascular risk, especially in patients with ACS
(39). However, in these studies, total plasma Lp-PLA2 but
ot HDL-Lp-PLA2 was determined. Thus, the effect of
arapladib on HDL-Lp-PLA2 remains to be determined.
The fact that darapladib reduces total plasma Lp-PLA2 by
59% to 66% at an oral daily dose of 160 mg for a period 3
to 12 months (37,38) could suggest that it may not
significantly reduce HDL-Lp-PLA2 activity, which repre-
ents 4.9% of the total plasma enzyme activity (24). In this
egard, it has been demonstrated that a selective Lp-PLA2
inhibitor, SB-222657, does not significantly influence
HDL-Lp-PLA2 activity (40). The clinical significance of
p-PLA2 in cardiovascular disease awaits to be proved in 2
phase 3 clinical trials, STABILITY (Stabilization of Ath-
erosclerotic Plaque by Initiation of Darapladib Therapy)
(41) and SOLID–TIMI 52 (Stabilization of Plaques Using
Darapladib–Thrombolysis in Myocardial Infarction 52)
(42), which are currently in progress. These studies will
determine whether inhibition of Lp-PLA2 activity with
darapladib safely reduces adverse cardiovascular events and
death.
Study limitations. The main limitation of our study was
the relatively small number of cardiac deaths. Although we
were able to detect significant associations between HDL-
Lp-PLA2 and cardiac deaths, these results should be inter-
preted with caution. A larger study is necessary to confirm
our results and improve the prognostic power of the studied
inflammatory markers before definitive conclusions can be
made. Another limitation is the reliance on death certifi-
cates to identify the exact cause of death, which is not always
reliable.
Clinical perspective. Epidemiological studies support an
association between plasma levels of Lp-PLA2 (which
epresent mainly the LDL-associated enzyme) and the risk
or occlusive coronary and vascular events. However, the
ole of Lp-PLA2 in atherosclerotic diseases may depend on
he type of lipoprotein with which it is associated. We
xamined the prognostic value of HDL-Lp-PLA2 in pa-
tients with stable CAD. We showed that HDL-Lp-PLA2
mass or activity is associated with lower risk for cardiac
death independently of other traditional risk factors for
CAD. This finding may be of particular importance in view
of the expected results of the phase 3 Stabilization of
Atherosclerotic Plaque by Initiation of Darapladib Therapy
clinical trial, which will determine whether inhibition of
Lp-PLA2 activity with darapladib safely reduces adverse
ardiovascular events and death. However, in this study asell as in the previous phase 2 clinical studies, the effect of
arapladib on HDL-Lp-PLA2 has not been determined.
urther studies are necessary to support the potential
athophysiological role and clinical utility of HDL-Lp-
LA2 in cardiovascular disease.
Conclusions
This prospective cohort of patients with stable CAD dem-
onstrated that HDL-Lp-PLA2 (mass or activity) is inversely
ssociated with future cardiac mortality independently of
he conventional risk factors, while HDL-Lp-PLA2 mass
preserves its predictive value even in patients with low HDL
cholesterol levels. These findings suggest that HDL-Lp-
PLA2 may be a clinically useful tool in the assessment of the
esidual cardiovascular risk, a hypothesis that needs to be
urther supported by large-scale clinical studies.
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